Bridges Investment Management Inc. Increases Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bridges Investment Management Inc. increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 111.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,509 shares of the medical equipment provider's stock after purchasing an additional 13,439 shares during the quarter. Bridges Investment Management Inc.'s holdings in Lantheus were worth $2,490,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LNTH. Nisa Investment Advisors LLC grew its stake in Lantheus by 2.1% during the 1st quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock worth $653,000 after buying an additional 139 shares during the last quarter. Linden Thomas Advisory Services LLC lifted its holdings in shares of Lantheus by 2.9% during the first quarter. Linden Thomas Advisory Services LLC now owns 22,569 shares of the medical equipment provider's stock valued at $2,203,000 after purchasing an additional 630 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in Lantheus by 5.7% in the 1st quarter. Envestnet Asset Management Inc. now owns 124,186 shares of the medical equipment provider's stock worth $12,121,000 after acquiring an additional 6,659 shares in the last quarter. Concurrent Investment Advisors LLC acquired a new position in Lantheus in the 1st quarter worth about $350,000. Finally, Moody Aldrich Partners LLC boosted its stake in Lantheus by 0.6% during the 1st quarter. Moody Aldrich Partners LLC now owns 36,205 shares of the medical equipment provider's stock valued at $3,534,000 after purchasing an additional 217 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Price Performance

LNTH traded down $2.27 during trading on Friday, reaching $81.56. The stock had a trading volume of 267,461 shares, compared to its average volume of 999,205. The stock has a market cap of $5.64 billion, a PE ratio of 23.17 and a beta of 0.12. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74. Lantheus Holdings, Inc. has a one year low of $73.11 and a one year high of $126.89. The business has a 50-day moving average of $80.81 and a 200-day moving average of $90.01.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The company had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. During the same quarter last year, the business earned $1.69 earnings per share. The business's quarterly revenue was up .8% on a year-over-year basis. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares in the company, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on LNTH. Truist Financial cut their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, B. Riley decreased their price objective on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lantheus presently has a consensus rating of "Buy" and an average target price of $130.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.